The recent surge in funding into niche pharmaceutical companies, particularly those focusing on novel therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." While the possibility for revolutionary treatments and substantial returns is clear, the associated risks are also considerable. Many of these